Non-small-cell lung cancer: how to manage EGFR-mutated disease

• Principais autores: Federica Pecci (Autor), Luca Cantini (Autor), Giulio Metro (Autor), Biagio Ricciuti (Autor), Giuseppe Lamberti (Autor), Ammad Ahmad Farooqi (Autor), Rossana Berardi (Autor)
• Formato: Livro
• Publicado em: BioExcel Publishing Ltd, 2022-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped the therapeutic algorithm both in the first-line...